AI Article Synopsis
Article Abstract
Objective: To evaluate the value of serum Human epididymis protein 4 (HE4) for predicting the resistance of ovarian cancer (OS) to platinum chemotherapy.
Method: We searched the MEDLINE (PubMed), EMBASE, Cochrane Central, Web of Science, SCOPUS, and CNKI databases and screened all studies evaluating serum HE4 for predicting OC resistance to treatment with platinum. Two researchers independently evaluated the quality of all eligible original studies using QUADAS-2. RevMan 5.4 was used to compile the quality evaluation form. We also performed a meta-analysis with STATA15.1, and Deek's funnel plots were used to detect any publication bias.
Results: Eight studies were included in the final meta-analysis. Our results showed that the sensitivity and specificity of preoperative serum HE4 in predicting the resistance of OC to platinum chemotherapy was 80% and 67%, respectively. The diagnostic odds ratio was 8, and the AUC was 0.78 (95% CI: 0.75-0.82), whereas the pooled sensitivity and specificity of serum HE4 after the third-cycle of chemotherapies for predicting chemoresistance in OC was 86% and 85%, respectively, with a diagnostic odds ratio of 33 and AUC = 0.92 (95% CI: 0.89 - 0.94).
Conclusion: HE4 may be an effective predictor of platinum-based chemotherapeutic resistance of OC. Serum HE4 levels after the third chemotherapy cycle may be indicative for clinical practice. Further research is needed to validate the significance of HE4 in the long-term management of OC.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, PROSPERO (CRD42021220099).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295753 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.703949 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Evaluation of Urinary HE4, CEA, ProGRP, CYFRA 21-1 and NSE in the Diagnosis of Lung Cancer.
Ann Clin Lab Sci
November 2024
Department of Clinical Laboratory Medicine, the First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Laboratory Medicine, Jinan, China
Objective: Urinary proteins are effective tumor biomarkers. Human epididymis protein 4 (HE4), progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), cytokeratin-19 fragment 21-1(CYFRA 21-1), and neuron-specific enolase (NSE) in serum, were proposed as tumor biomarkers of lung cancer. Our aim was to identify the urine protein biomarkers that can distinguish patients with lung cancer from healthy individuals and/or patients with benign lung disease with a high level of sensitivity and specificity.
View Article and Find Full Text PDFMulticenter study of ovarian cancer score for diagnosing ovarian cancer.
Gynecol Oncol
January 2025
Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China; Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China; Organoid Transformational Research Center, Chongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis, Chongqing University Cancer Hospital, Chongqing, China. Electronic address:
Background: Early detection is crucial for improving survival of patients with ovarian cancer (OC), yet current diagnostic tools lack adequate sensitivity and specificity, especially for early stage disease. The study aimed to validate the serum small extracellular vesicles (sEV) protein based Ovarian Cancer Score (OCS) in detecting OC.
Methods: This multicenter study included 1183 adult females with adnexal masses from four hospitals in China (October 2019-April 2023).
Evaluation of serum human epididymis protein 4 in children with chronic liver diseases.
Scand J Clin Lab Invest
December 2024
Clinical and Chemical Pathology Department, Faculty of Medicine, Benha University, Benha, Egypt.
The aim of this study was to evaluate the role of serum human epididymis protein 4 (HE4) as a non-invasive biomarker for the diagnosis of liver fibrosis in children with chronic liver diseases (CLD). This case-control study was conducted at Benha University Hospital, Egypt, involving 60 children with CLD and 60 healthy children as a control group. HE4 levels were measured by ELISA and compared with liver biopsy results.
View Article and Find Full Text PDFHuman epididymitis protein 4 as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathies.
Clin Exp Rheumatol
December 2024
Department of Medicine-DIMED, Padova University Hospital, Padova, Italy.
Article Synopsis
- HE4 is a protein that helps promote fibrosis by preventing collagen breakdown; this study aimed to evaluate HE4 as a biomarker for interstitial lung disease (ILD) in patients with idiopathic inflammatory myopathies (IIMs).
- Researchers enrolled 90 IIMs patients and 42 healthy controls, finding that serum HE4 levels were significantly higher in patients with IIMs, particularly in those diagnosed with ILD.
- The study concluded that HE4 levels could serve as a useful biomarker for detecting and assessing ILD in IIMs patients, although there was no significant link between baseline HE4 and progressive fibrosing ILD in follow-up cases.
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.
PLoS One
December 2024
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States of America.
Ovarian cancer is the leading cause of death among gynecologic malignancies. Despite recent advancements in targeted therapies such as PARP inhibitors, recurrence is common and frequently resistant to existing therapies. A powerful diagnostic tool, coupled with a comprehensive understanding of its implications, is crucial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!